Our narrow economic moat rating for UnitedHealth Group reflects our generally narrow-moat view of the US health insurance and PBM industries that includes an unclear outlook for economic profitability ...

UnitedHealth posted a better-than-expected profit in the final quarter of 2024, but a nagging rise in medical costs and care ...

In an investor call, Andrew Witty promised full transparency and 100% pass-through rebates for prescription drugs by 2028.